Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib, Lenalidomide and Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
NCT02460276Phase 2Completed
- Sponsor
- Skåne University Hospital
- Start
- Apr 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of ibrutinib, lenalidomide, rituximab in mantle cell lymphoma (MCL), sponsored by Skåne University Hospital. Started Apr 2015; status: completed.
02
Drugs
ibrutiniblenalidomiderituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02460276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460276.